# RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)

> **NCT07009860** · PHASE2 · RECRUITING · sponsor: **Altimmune, Inc.** · enrollment: 100 (estimated)

## Conditions studied

- Alcohol Liver Disease

## Interventions

- **DRUG:** Pemvidutide
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT07009860
- **Lead sponsor:** Altimmune, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-06-16
- **Primary completion:** 2027-03-31
- **Final completion:** 2027-08-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07009860

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07009860, "RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)". Retrieved via AI Analytics 2026-07-30 from https://api.ai-analytics.org/clinical/NCT07009860. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*